Literature DB >> 15880305

[Therapy of pain syndromes in multiple sclerosis -- an overview with evidence-based recommendations].

W Pöllmann1, W Feneberg, A Steinbrecher, M R Haupts, T Henze.   

Abstract

While pain is a common problem in multiple sclerosis (MS) patients, it is frequently overlooked and has to be asked for actively. Pain can be classified into 4 diagnostically and therapeutically relevant categories. 1. PAIN DIRECTLY RELATED TO MS: Painful paroxysmal symptoms like trigeminal neuralgia or painful tonic spasms are treated with carbamazepine as first choice, or lamotrigine, gabapentin, oxcarbazepine and other anticonvulsants. Painful "burning" dysaesthesia, the most frequent chronic pain syndrome, are treated with tricyclic antidepressants or carbamazepine, further options include gabapentin or lamotrigine. While escalation therapy may require opioids, the role of cannabinoids in the treatment of pain still has to be determined. 2. PAIN INDIRECTLY RELATED TO MS: Pain related to spasticity often improves with adequate physiotherapy. Drug treatment includes antispastic agents like baclofen or tizanidine, alternatively gabapentin. In severe cases botulinum toxin injections or intrathecal baclofen merit consideration. Physiotherapy and physical therapy may ameliorate malposition-induced joint and muscle pain. Moreover, painful pressure lesions should be avoided using optimally adjusted aids. 3. Treatment-related pain can occur with subcutaneous injections of beta interferons or glatiramer acetate and may be reduced by optimizing the injection technique and by local cooling. Systemic side effects of interferons like myalgias can be reduced by paracetamol or ibuprofen. 4. Pain unrelated to MS such as back pain or headache are frequent in MS patients and may be worsened by the disease. Treatment should be follow established guidelines. In summary, a careful analysis of the pain syndrome will allow the design of the appropriate treatment plan using various medical and non-medical options and thus will help to ameliorate the patients' quality of life.

Entities:  

Mesh:

Year:  2005        PMID: 15880305     DOI: 10.1055/s-2004-830193

Source DB:  PubMed          Journal:  Fortschr Neurol Psychiatr        ISSN: 0720-4299            Impact factor:   0.752


  6 in total

Review 1.  Botulinum toxin in multiple sclerosis.

Authors:  Wolfgang H Jost
Journal:  J Neurol       Date:  2006-02       Impact factor: 4.849

2.  Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Authors:  João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

Review 3.  Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.

Authors:  Dirk Dressler; Roongroj Bhidayasiri; Saeed Bohlega; Abderrahmane Chahidi; Tae Mo Chung; Markus Ebke; L Jorge Jacinto; Ryuji Kaji; Serdar Koçer; Petr Kanovsky; Federico Micheli; Olga Orlova; Sebastian Paus; Zvezdan Pirtosek; Maja Relja; Raymond L Rosales; José Alberto Sagástegui-Rodríguez; Paul W Schoenle; Gholam Ali Shahidi; Sofia Timerbaeva; Uwe Walter; Fereshte Adib Saberi
Journal:  J Neurol       Date:  2016-10-27       Impact factor: 4.849

Review 4.  Current management of pain associated with multiple sclerosis.

Authors:  Walter Pöllmann; Wolfgang Feneberg
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Willingness to pay for a treatment for pain in multiple sclerosis.

Authors:  Michael Iskedjian; Olivier Desjardins; Charles Piwko; Basil Bereza; Barbara Jaszewski; Thomas R Einarson
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

6.  Pain due to multiple sclerosis: analysis of the prevalence and economic burden in Canada.

Authors:  Charles Piwko; Olivier B Desjardins; Basil G Bereza; Marcio Machado; Barbara Jaszewski; Mark S Freedman; Thomas R Einarson; Michael Iskedjian
Journal:  Pain Res Manag       Date:  2007       Impact factor: 3.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.